Guggenheim on Larimar Therapeutics (LRMR): 'remains on track to present initial OLE data in Sept 2025'
Tweet Send to a Friend
Guggenheim analyst Yatin Suneja reiterated a Buy rating and $26.00 price target on Larimar Therapeutics (NASDAQ: LRMR).The analyst comments "Key ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
